English
Insider transactions
EDGARCognition Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-22.
- Open-market purchases (code P)
- 3 transactions, 29,175 shares
- Sum of shares × price per share: 32,492.5
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–26 of 26
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 Filed 2026-06-22 | Wallace Peggy Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 111,461 | Direct (D) | No | F1
| Open filing 0001104659-26-076472 Read from the filing’s XML Dispute this row |
| 2026-06-17 Filed 2026-06-22 | Khattar Jack A. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 73,500 | Direct (D) | No | F1
| Open filing 0001104659-26-076477 Read from the filing’s XML Dispute this row |
| 2026-06-17 Filed 2026-06-22 | RICHSTONE ELLEN B Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 83,500 | Direct (D) | No | F1
| Open filing 0001104659-26-076470 Read from the filing’s XML Dispute this row |
| 2026-06-17 Filed 2026-06-22 | Monia Brett P Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 73,500 | Direct (D) | No | F1
| Open filing 0001104659-26-076475 Read from the filing’s XML Dispute this row |
| 2026-06-17 Filed 2026-06-22 | Fletcher Aaron G.L. Director · 10% ownerBIOS Capital Management, LP Director · 10% ownerBIOS Advisors GP, LLC Director · 10% ownerBios Equity Partners, LP Director · 10% ownerBIOS Fund I, LP Director · 10% ownerBIOS Fund II QP, LP Director · 10% ownerBIOS Memory SPV I, LP Director · 10% ownerBios Equity Partners II, LP Director · 10% ownerBIOS Fund II, LP Director · 10% ownerBIOS Fund I QP, LP Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 0 | — | 81,229 | Direct (D) | No | F1, F2
| Open filing 0001789490-26-000002 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-04 | Doyle John Brendan Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 8,567 | 1.28 | 10,965.76Derived: shares × price per share. Exact value 10965.76. | 618,942 | Direct (D) | No | F1
| Open filing 0001104659-26-054858 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Doyle John Brendan Officer: Chief Financial Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 10,000 | 1.13 | 11,300Derived: shares × price per share. Exact value 11300.00. | 627,509 | Direct (D) | No | — | Open filing 0001104659-26-045511 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Caggiano Anthony Officer: Chief Medical Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 10,000 | 1.11 | 11,100Derived: shares × price per share. Exact value 11100.00. | 874,906 | Direct (D) | No | — | Open filing 0001104659-26-045499 Read from the filing’s XML Dispute this row |
| 2026-04-16 Filed 2026-04-20 | Ricciardi Lisa Director · Officer: CEO President | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 9,175 | 1.10 | 10,092.5Derived: shares × price per share. Exact value 10092.50. | 1,715,851 | Direct (D) | No | — | Open filing 0001104659-26-045502 Read from the filing’s XML Dispute this row |
| 2026-02-15 Filed 2026-02-18 | Ricciardi Lisa Director · Officer: CEO President | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 5,850 | 1.12 | 6,552Derived: shares × price per share. Exact value 6552.00. | 1,706,676 | Direct (D) | No | F1
| Open filing 0001104659-26-017070 Read from the filing’s XML Dispute this row |
| 2026-02-15 Filed 2026-02-18 | Doyle John Brendan Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 1,560 | 1.12 | 1,747.2Derived: shares × price per share. Exact value 1747.20. | 617,509 | Direct (D) | No | F1
| Open filing 0001104659-26-017068 Read from the filing’s XML Dispute this row |
| 2026-02-15 Filed 2026-02-18 | Caggiano Anthony Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 4,680 | 1.12 | 5,241.6Derived: shares × price per share. Exact value 5241.60. | 864,906 | Direct (D) | No | F1
| Open filing 0001104659-26-017063 Read from the filing’s XML Dispute this row |
| 2026-02-04 Filed 2026-02-05 | Doyle John Brendan Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 26,921 | 1.03 | 27,728.63Derived: shares × price per share. Exact value 27728.63. | 619,069 | Direct (D) | No | F2
| Open filing 0001104659-26-011074 Read from the filing’s XML Dispute this row |
| 2026-02-04 Filed 2026-02-05 | Ricciardi Lisa Director · Officer: CEO President | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 51,704 | 1.03 | 53,255.12Derived: shares × price per share. Exact value 53255.12. | 1,712,526 | Direct (D) | No | F2
| Open filing 0001104659-26-011075 Read from the filing’s XML Dispute this row |
| 2026-02-04 Filed 2026-02-05 | Caggiano Anthony Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 26,919 | 1.03 | 27,726.57Derived: shares × price per share. Exact value 27726.57. | 869,586 | Direct (D) | No | F2
| Open filing 0001104659-26-011073 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Doyle John Brendan Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 200,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 645,990 | Direct (D) | No | F1
| Open filing 0001104659-26-011074 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Ricciardi Lisa Director · Officer: CEO President | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 800,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 1,790,266 | Direct (D) | No | F1
| Open filing 0001104659-26-011075 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Ricciardi Lisa Director · Officer: CEO President | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 26,036 | 1.12 | 29,160.32Derived: shares × price per share. Exact value 29160.32. | 1,764,230 | Direct (D) | No | F2
| Open filing 0001104659-26-011075 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Caggiano Anthony Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 400,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 907,993 | Direct (D) | No | F1
| Open filing 0001104659-26-011073 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Caggiano Anthony Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 11,488 | 1.12 | 12,866.56Derived: shares × price per share. Exact value 12866.56. | 896,505 | Direct (D) | No | F2
| Open filing 0001104659-26-011073 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Ricciardi Lisa Director · Officer: CEO President | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 75,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 1,013,666 | Direct (D) | No | F1
| Open filing 0001104659-25-123727 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Ricciardi Lisa Director · Officer: CEO President | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 23,400 | 1.50 | 35,100Derived: shares × price per share. Exact value 35100.00. | 990,266 | Direct (D) | No | F2
| Open filing 0001104659-25-123727 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Caggiano Anthony Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 65,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 528,273 | Direct (D) | No | F1
| Open filing 0001104659-25-123722 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Caggiano Anthony Officer: Chief Medical Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 20,280 | 1.50 | 30,420Derived: shares × price per share. Exact value 30420.00. | 507,993 | Direct (D) | No | F2
| Open filing 0001104659-25-123722 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Doyle John Brendan Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 30,000 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 455,350 | Direct (D) | No | F1
| Open filing 0001104659-25-123721 Read from the filing’s XML Dispute this row |
| 2025-12-18 Filed 2025-12-22 | Doyle John Brendan Officer: Chief Financial Officer | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 9,360 | 1.50 | 14,040Derived: shares × price per share. Exact value 14040.00. | 445,990 | Direct (D) | No | F2
| Open filing 0001104659-25-123721 Read from the filing’s XML Dispute this row |
Latest reported holdings
What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.
| Reporting owner | Security | Shares owned after | Direct or indirect | Source |
|---|---|---|---|---|
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Advisors GP, LLC Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Capital Management, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Equity Partners III, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I QP, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund I, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund II NT, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II QP, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Fund II, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III NT, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III QP, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Fund III, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| BIOS Memory SPV I, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BIOS Memory SPV II, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| BP Directors, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners II, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| Bios Equity Partners, LP Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| Caggiano Anthony Officer: Chief Medical Officer | Common Stock | 874,906 | D | As of 2026-04-16 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| Cavu Advisors, LLC Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| Cavu Management, LP Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| Doyle John Brendan Officer: Chief Financial Officer | Common Stock | 618,942 | D | As of 2026-05-01 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Stock Option (right to buy) Derivative security · underlying Common Stock | 0 | D | As of 2025-09-19 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 326,732 | I By Bios Fund III NT, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 2,021,907 | I By Bios Fund III QP, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2026-06-22 Open filing 4 |
| Fletcher Aaron G.L. Director · 10% owner | Common Stock | 81,229 | D | As of 2026-06-17 Open filing 4 |
| Khattar Jack A. Director | Common Stock | 73,500 | D | As of 2026-06-17 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 500,095 | I By Bios Clinical Opportunity Fund, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 245,029 | I By Bios Fund I QP, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 418,926 | I By Bios Fund I, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 34,238 | I By Bios Fund II NT, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 255,765 | I By Bios Fund II QP, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 78,298 | I By Bios Fund II, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 326,733 | I By Bios Fund III NT, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 2,021,906 | I By Bios Fund III QP, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 309,748 | I By Bios Fund III, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 1,424,014 | I By Bios Memory SPV I, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 385,248 | I By Bios Memory SPV II, LP | As of 2025-06-20 Open filing 4 |
| Kreis Leslie W. Director · 10% owner | Common Stock | 48,500 | I See Footnote | As of 2025-06-18 Open filing 4 |
| Monia Brett P Director | Common Stock | 73,500 | D | As of 2026-06-17 Open filing 4 |
| RICHSTONE ELLEN B Director | Common Stock | 83,500 | D | As of 2026-06-17 Open filing 4 |
| Ricciardi Lisa Director · Officer: CEO President | Common Stock | 38,851 | I By Spouse | As of 2026-04-20 Open filing 4 |
| Ricciardi Lisa Director · Officer: CEO President | Common Stock | 1,715,851 | D | As of 2026-04-16 Open filing 4 |
| Ricciardi Lisa Director · Officer: CEO President | Common Stock | 38,851 | I By Spouse | As of 2025-01-31 Open filing 4 |
| Wallace Peggy Director | Common Stock | 111,461 | D | As of 2026-06-17 Open filing 4 |
Joint filers each report the same shares, so rows are not added together.
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–50 of 78
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| BIOS Capital Management, LP Partly reported under another manager | 6,000,000 SH | 5,760,000 dollars | Unchanged Prior quarter: 6,000,000 | Open filing 0001813845-26-000009 Filed 2026-11-13 Dispute this row |
| DAVENPORT Co LLC | 4,248,410 SH | 4,078,474 dollars | Lower by 11,101 Prior quarter: 4,259,511 | Open filing 0000887777-26-000029 Filed 2026-10-14 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,438,775 SH | 3,301,224 dollars | Unchanged Prior quarter: 3,438,775 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 1,253,474 SH | 1,203,335 dollars | Lower by 8,519 Prior quarter: 1,261,993 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| Chescapmanager LLC Partly reported under another manager | 997,029 SH | 957,148 dollars | Unchanged Prior quarter: 997,029 | Open filing 0001140361-26-043745 Filed 2026-11-13 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 911,526 SH | 875,525 dollars | Higher by 1,520 Prior quarter: 910,006 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager | 587,171 SH | 563,684 dollars | Lower by 106,117 Prior quarter: 693,288 | Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row |
| Hilton Capital Management, LLC | 548,950 SH | 526,992 dollars | Unchanged Prior quarter: 548,950 | Open filing 0001172661-26-004953 Filed 2026-11-12 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 508,220 SH | 487,891 dollars | Unchanged Prior quarter: 508,220 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| CM Management, LLC | 425,000 SH | 408,000 dollars | Lower by 25,000 Prior quarter: 450,000 | Open filing 0001841857-26-000004 Filed 2026-11-12 Dispute this row |
| Sigma Planning Corp | 364,765 SH | 350,174 dollars | Higher by 2,500 Prior quarter: 362,265 | Open filing 0001420506-26-002366 Filed 2026-10-23 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 348,983 SH | 335,024 dollars | Unchanged Prior quarter: 348,983 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 230,500 SH | 221,280 dollars | Lower by 90,000 Prior quarter: 320,500 | Open filing 0000919574-26-007782 Filed 2026-11-13 Dispute this row |
| Dauntless Investment Group, LLC | 207,714 SH | 199,405 dollars | Lower by 163,987 Prior quarter: 371,701 | Open filing 0002071844-26-001894 Filed 2026-11-16 Dispute this row |
| AMERICAN FINANCIAL GROUP INC Partly reported under another manager | 205,000 SH | 196,800 dollars | Unchanged Prior quarter: 205,000 | Open filing 0001042046-26-000037 Filed 2026-11-12 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 178,202 SH | 171,074 dollars | Unchanged Prior quarter: 178,202 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Partly reported under another manager | 152,114 SH | 146,029 dollars | Not in the prior quarter’s filings read | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| Texas Capital Bank Wealth Management Services Inc | 143,296 SH | 137,564 dollars | Unchanged Prior quarter: 143,296 | Open filing 0001802655-26-000009 Filed 2026-11-09 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 84,940 SH | 81,542 dollars | Unchanged Prior quarter: 84,940 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| Corient Private Wealth LP | 81,287 SH | 78,036 dollars | Higher by 3,061 Prior quarter: 78,226 | Open filing 0001948780-26-000012 Filed 2026-11-16 Dispute this row |
| Voss Capital, LP | 71,512 SH | 68,652 dollars | Lower by 103,488 Prior quarter: 175,000 | Open filing 0001730145-26-000006 Filed 2026-11-16 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 71,065 SH | 68,222 dollars | Not in the prior quarter’s filings read | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 68,373 SH | 65,638 dollars | Higher by 40,500 Prior quarter: 27,873 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| McAdam, LLC | 59,004 SH | 56,644 dollars | Lower by 5,549 Prior quarter: 64,553 | Open filing 0001580642-26-007004 Filed 2026-10-21 Dispute this row |
| FCA CORP /TX | 52,536 SH | 50,435 dollars | Unchanged Prior quarter: 52,536 | Open filing 0001104659-26-125595 Filed 2026-11-12 Dispute this row |
| JONES FINANCIAL COMPANIES LLLP Partly reported under another manager | 50,661 SH | 47,419 dollars | Higher by 10,017 Prior quarter: 40,644 | Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row |
| BlueStem Wealth Partners, LLC | 50,000 SH | 48,000 dollars | Not in the prior quarter’s filings read | Open filing 0001765380-26-000496 Filed 2026-11-13 Dispute this row |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 48,000 SH | 46,080 dollars | Unchanged Prior quarter: 48,000 | Open filing 0001085146-26-000916 Filed 2026-10-27 Dispute this row |
| Lido Advisors, LLC | 46,149 SH | 44,303 dollars | Not in the prior quarter’s filings read | Open filing 0001172661-26-004854 Filed 2026-11-04 Dispute this row |
| Bangor Savings Bank Partly reported under another manager | 40,519 SH | 38,898 dollars | Unchanged Prior quarter: 40,519 | Open filing 0001352675-26-000007 Filed 2026-10-06 Dispute this row |
| Essex Financial Services, Inc. | 40,000 SH | 38,400 dollars | Unchanged Prior quarter: 40,000 | Open filing 0001951757-26-001932 Filed 2026-11-13 Dispute this row |
| StoneX Group Inc. Partly reported under another manager | 30,945 SH | 29,840 dollars | Not in the prior quarter’s filings read | Open filing 0000913760-26-000042 Filed 2026-11-03 Dispute this row |
| Spark Investment Management LLC | 30,200 SH | 28,992 dollars | Not in the prior quarter’s filings read | Open filing 0000899140-26-001312 Filed 2026-11-13 Dispute this row |
| GABELLI FUNDS LLC | 30,000 SH | 28,800 dollars | Unchanged Prior quarter: 30,000 | Open filing 0001140361-26-043450 Filed 2026-11-12 Dispute this row |
| Bryn Mawr Trust Advisors, LLC | 29,050 SH | 27,888 dollars | Unchanged Prior quarter: 29,050 | Open filing 0001085146-26-000927 Filed 2026-11-04 Dispute this row |
| CITIZENS FINANCIAL GROUP INC/RI Partly reported under another manager | 27,358 SH | 26,264 dollars | Higher by 13,679 Prior quarter: 13,679 | Open filing 0000759944-26-000210 Filed 2026-10-23 Dispute this row |
| HighTower Advisors, LLC | 26,500 SH | 25,440 dollars | Unchanged Prior quarter: 26,500 | Open filing 0001085146-26-000933 Filed 2026-11-10 Dispute this row |
| PRIVATE MANAGEMENT GROUP INC Partly reported under another manager | 24,000 SH | 23,040 dollars | Unchanged Prior quarter: 24,000 | Open filing 0001142031-26-000022 Filed 2026-11-04 Dispute this row |
| Vanguard Global Advisers, LLC | 23,641 SH | 22,695 dollars | Unchanged Prior quarter: 23,641 | Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row |
| CWA Asset Management Group, LLC Partly reported under another manager | 23,000 SH | 22,080 dollars | Unchanged Prior quarter: 23,000 | Open filing 0001667134-26-000006 Filed 2026-10-19 Dispute this row |
| Virtu Financial LLC Partly reported under another manager | 22,742 SH | 22 dollars | Lower by 60,692 Prior quarter: 83,434 | Open filing 0001533964-26-000015 Filed 2026-11-17 Dispute this row |
| Creative Planning | 22,200 SH | 21,312 dollars | Unchanged Prior quarter: 22,200 | Open filing 0001540235-26-000006 Filed 2026-11-02 Dispute this row |
| XTX Topco Ltd Partly reported under another manager | 21,022 SH | 20,181 dollars | Lower by 57,449 Prior quarter: 78,471 | Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row |
| Cetera Investment Advisers | 20,830 SH | 19,997 dollars | Higher by 980 Prior quarter: 19,850 | Open filing 0001666741-26-000005 Filed 2026-11-13 Dispute this row |
| Vestmark Advisory Solutions, Inc. Partly reported under another manager | 20,080 SH | 19,276 dollars | Higher by 10,040 Prior quarter: 10,040 | Open filing 0001172661-26-005184 Filed 2026-11-16 Dispute this row |
| GAMCO INVESTORS, INC. ET AL | 20,000 SH | 19,200 dollars | Unchanged Prior quarter: 20,000 | Open filing 0001140361-26-043449 Filed 2026-11-12 Dispute this row |
| Rockefeller Capital Management L.P. Partly reported under another manager | 19,231 SH | 18,462 dollars | Unchanged Prior quarter: 19,231 | Open filing 0001739439-26-000009 Filed 2026-11-13 Dispute this row |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 17,467 SH | 16,768 dollars | Unchanged Prior quarter: 17,467 | Open filing 0001085146-26-000940 Filed 2026-11-13 Dispute this row |
| Focus Partners Wealth | 17,250 SH | 16,560 dollars | Unchanged Prior quarter: 17,250 | Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row |
| MERCER GLOBAL ADVISORS INC /ADV Partly reported under another manager | 15,951 SH | 15,313 dollars | Unchanged Prior quarter: 15,951 | Open filing 0000853758-26-000020 Filed 2026-11-16 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Sixth Street Partners Management Company, L.P. 84,940 SH
- Circle Wealth Management, LLC 48,842 SH
- Qube Research Technologies Ltd 21,800 SH
- Robertson Stephens Wealth Management, LLC 10,000 SH
- CITIGROUP INC 7,620 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Institutional ownership reported on Form 13F
13F filers report holding between 7.20% and 23.27% of shares outstanding.
Quarter ending 2026-09-30, against 95,100,822 shares on the cover dated 2026-11-02.
- The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
- Neither includes holders that do not file Form 13F, or managers below the filing threshold.
| Quarter | Managers holding | Shares, at least | Shares, at most | Filings read |
|---|---|---|---|---|
| 2026-09-30 | 78 | 6,847,713 | 22,128,751 | 8,935 |
| 2026-06-30 | 67 | 7,232,430 | 22,672,075 | 9,178 |
| 2026-03-31 | 75 | 5,750,545 | 21,417,693 | 9,173 |
| 2025-12-31 | 78 | 5,954,554 | 21,497,402 | 9,222 |
| 2025-09-30 | 69 | 5,716,195 | 21,285,146 | 8,469 |
| 2025-06-30 | 50 | 1,543,388 | 11,241,508 | 8,516 |
| 2025-03-31 | 52 | 1,818,484 | 11,627,983 | 8,518 |
| 2024-12-31 | 46 | 2,352,951 | 11,088,342 | 8,580 |
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| BIOS MEMORY SPV I, LP Common Stock, par value $0.001 per share | 1.6 | 1,424,014.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS MEMORY SPV II, LP Common Stock, par value $0.001 per share | 0.4 | 385,248.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND I, LP Common Stock, par value $0.001 per share | 0.5 | 418,926.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND I QP, LP Common Stock, par value $0.001 per share | 0.3 | 245,029.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BP DIRECTORS, LP Common Stock, par value $0.001 per share | 0.04 | 32,328.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND II, LP Common Stock, par value $0.001 per share | 0.1 | 78,298.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND II QP, LP Common Stock, par value $0.001 per share | 0.3 | 255,765.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND II NT, LP Common Stock, par value $0.001 per share | 0.04 | 34,238.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND III, LP Common Stock, par value $0.001 per share | 0.4 | 309,748.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND III QP, LP Common Stock, par value $0.001 per share | 2.3 | 2,021,906.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS FUND III NT, LP Common Stock, par value $0.001 per share | 0.4 | 326,733.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS CLINICAL OPPORTUNITY FUND, LP Common Stock, par value $0.001 per share | 0.6 | 500,095.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS EQUITY PARTNERS, LP Common Stock, par value $0.001 per share | 1.2 | 1,081,531.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS EQUITY PARTNERS II, LP Common Stock, par value $0.001 per share | 0.4 | 368,301.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS EQUITY PARTNERS III, LP Common Stock, par value $0.001 per share | 3.0 | 2,658,387.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS EQUITY COF, LP Common Stock, par value $0.001 per share | 0.6 | 500,095.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| CAVU MANAGEMENT, LP Common Stock, par value $0.001 per share | 6.3 | 5,532,233.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS CAPITAL MANAGEMENT, LP Common Stock, par value $0.001 per share | 6.8 | 6,032,328.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| CAVU ADVISORS, LLC Common Stock, par value $0.001 per share | 6.3 | 5,532,233.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| BIOS ADVISORS GP, LLC Common Stock, par value $0.001 per share | 6.8 | 6,032,328.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| LESLIE W. KREIS Common Stock, par value $0.001 per share | 6.3 | 5,532,233.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| AARON G.L. FLETCHER Common Stock, par value $0.001 per share | 6.9 | 6,059,555.00 | 09/19/2025 Filed 2025-09-23 | SCHEDULE 13D/AAmendment 4 | Open filing 0001104659-25-092675 Dispute this row |
| AIGH Capital Management, LLC Common Shares | 4.8 | 1,448,270 | — Filed 2024-02-07 | SC 13G/AAmendment 2Read from the cover page text | Open filing 0001493152-24-005342 Dispute this row |
| Orin Hirschman Common Shares | 4.8 | 1,448,270 | — Filed 2024-02-07 | SC 13G/AAmendment 2Read from the cover page text | Open filing 0001493152-24-005342 Dispute this row |
| Pathstone Family Office, LLC Common stock | 7.53 | 2,205,377 | — Filed 2024-01-19 | SC 13GRead from the cover page text | Open filing 0001085146-24-000333 Dispute this row |
| BIOS MEMORY SPV I, LP Common Stock, par value $0.001 per share | 4.6 | 1,424,014 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS MEMORY SPV II, LP Common Stock, par value $0.001 per share | 1.2 | 385,248 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND I, LP Common Stock, par value $0.001 per share | 1.4 | 418,926 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND I QP, LP Common Stock, par value $0.001 per share | 0.8 | 245,029 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND II, LP Common Stock, par value $0.001 per share | 0.3 | 78,298 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND II QP, LP Common Stock, par value $0.001 per share | 0.8 | 255,765 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND II NT, LP Common Stock, par value $0.001 per share | 0.1 | 34,238 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND III, LP Common Stock, par value $0.001 per share | 1.0 | 309,748 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND III QP, LP Common Stock, par value $0.001 per share | 6.5 | 2,021,906 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS FUND III NT, LP Common Stock, par value $0.001 per share | 1.1 | 326,733 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS CLINICAL OPPORTUNITY FUND, LP Common Stock, par value $0.001 per share | 1.6 | 500,095 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BP DIRECTORS, LP Common Stock, par value $0.001 per share | 0.02 | 6,000 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS EQUITY PARTNERS, LP Common Stock, par value $0.001 per share | 3.4 | 1,055,203 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS EQUITY PARTNERS II, LP Common Stock, par value $0.001 per share | 1.2 | 368,301 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS EQUITY PARTNERS III, LP Common Stock, par value $0.001 per share | 8.6 | 2,658,387 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS EQUITY COF, LP Common Stock, par value $0.001 per share | 1.6 | 500,095 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| CAVU MANAGEMENT, LP Common Stock, par value $0.001 per share | 17.8 | 5,505,905 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS CAPITAL MANAGEMENT, LP Common Stock, par value $0.001 per share | 19.4 | 6,006,000 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| CAVU ADVISORS, LLC Common Stock, par value $0.001 per share | 17.8 | 5,505,905 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| BIOS ADVISORS GP, LLC Common Stock, par value $0.001 per share | 19.4 | 6,006,000 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| LESLIE WAYNE KREIS, JR. Common Stock, par value $0.001 per share | 17.8 | 5,505,905 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| AARON GLENN LOUIS FLETCHER Common Stock, par value $0.001 per share | 19.4 | 6,006,000 | — Filed 2023-11-13 | SC 13D/AAmendment 3Read from the cover page text | Open filing 0001104659-23-117349 Dispute this row |
| AIGH Capital Management, LLC Common Shares | 7.0 | 2,037,853 | — Filed 2023-02-15 | SC 13G/AAmendment 1Read from the cover page text | Open filing 0001493152-23-005130 Dispute this row |
| Orin Hirschman Common Shares | 7.0 | 2,037,853 | — Filed 2023-02-15 | SC 13G/AAmendment 1Read from the cover page text | Open filing 0001493152-23-005130 Dispute this row |
| BIOS MEMORY SPV I, LP Common Stock, par value $0.001 per share | 5.9 | 1,424,014 | — Filed 2022-12-05 | SC 13D/AAmendment 2Read from the cover page text | Open filing 0001104659-22-124618 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 258,595 |
| 2016 | 246,472 |
| 2017 | 244,814 |
| 2018 | 245,575 |
| 2019 | 238,619 |
| 2020 | 249,093 |
| 2021 | 274,850 |
| 2022 | 257,922 |
| 2023 | 253,676 |
| 2024 | 261,106 |
| 2025 | 235,525 |
| 2026 | 263,830 |
Filings made before the SEC required XML are listed, not extracted.